{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:55:55Z","timestamp":1790690155181,"version":"4.1.0"},"reference-count":186,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T00:00:00Z","timestamp":1782604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":93,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Siksha 'O' Anusandhan Deemed To Be University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Proteom"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1186\/s12014-026-09617-0","type":"journal-article","created":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T19:23:47Z","timestamp":1782674627000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comprehensive biochemical insights into derivatives of PSA and glycosylation-specific changes in PSA: role in diagnosis and management of prostate cancer"],"prefix":"10.1186","volume":"23","author":[{"given":"Laxmidhar","family":"Das","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,28]]},"reference":[{"key":"9617_CR1","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.eururo.2025.05.038","volume":"88","author":"IG Schoots","year":"2025","unstructured":"Schoots IG, Ahmed HU, Albers P, Asbach P, van den Bergh RCN, Godtman RA, et al. Magnetic Resonance Imaging\u2013based Biopsy Strategies in Prostate Cancer Screening: A Systematic Review. Eur Urol. 2025;88:247\u201360. https:\/\/doi.org\/10.1016\/j.eururo.2025.05.038.","journal-title":"Eur Urol"},{"key":"9617_CR2","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.3390\/diagnostics13132283","volume":"13","author":"M Zhu","year":"2023","unstructured":"Zhu M, Liang Z, Feng T, Mai Z, Jin S, Wu L, et al. Up-to-Date Imaging and Diagnostic Techniques for Prostate Cancer: A Literature Review. Diagnostics. 2023;13:2283. https:\/\/doi.org\/10.3390\/diagnostics13132283.","journal-title":"Diagnostics"},{"key":"9617_CR3","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s13244-024-01699-4","volume":"15","author":"E Guo","year":"2024","unstructured":"Guo E, Xu L, Zhang D, Zhang J, Zhang X, Bai X, et al. Diagnostic performance of MRI in detecting prostate cancer in patients with prostate-specific antigen levels of 4\u201310 ng\/mL: a systematic review and meta-analysis. Insights Imaging. 2024;15:147. https:\/\/doi.org\/10.1186\/s13244-024-01699-4.","journal-title":"Insights Imaging"},{"key":"9617_CR4","doi-asserted-by":"publisher","first-page":"3682","DOI":"10.3390\/cancers15143682","volume":"15","author":"A \u017burowska","year":"2023","unstructured":"\u017burowska A, P\u0119ksa R, Bie\u0144kowski M, Skrobisz K, Sowa M, Matuszewski M, et al. Prostate Cancer and Its Mimics\u2014A. Pict Rev Cancers (Basel). 2023;15:3682. https:\/\/doi.org\/10.3390\/cancers15143682.","journal-title":"Pict Rev Cancers (Basel)"},{"key":"9617_CR5","doi-asserted-by":"publisher","first-page":"6168","DOI":"10.1007\/s00330-024-10626-6","volume":"34","author":"AR Padhani","year":"2024","unstructured":"Padhani AR, Godtman RA, Schoots IG. Key learning on the promise and limitations of MRI in prostate cancer screening. Eur Radiol. 2024;34:6168\u201374. https:\/\/doi.org\/10.1007\/s00330-024-10626-6.","journal-title":"Eur Radiol"},{"key":"9617_CR6","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.urolonc.2021.08.006","volume":"41","author":"EH Kim","year":"2023","unstructured":"Kim EH, Andriole GL. Should men undergo MRI before prostate biopsy \u2013 CON. Urologic Oncology: Seminars Original Investigations. 2023;41:92\u20135. https:\/\/doi.org\/10.1016\/j.urolonc.2021.08.006.","journal-title":"Urologic Oncology: Seminars Original Investigations"},{"key":"9617_CR7","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.prnil.2024.03.005","volume":"12","author":"K Arulraj","year":"2024","unstructured":"Arulraj K, Sharma S, Das CJ, Seth A, Kumar R. Negative magnetic resonance imaging cannot be used to omit an initial prostate biopsy - An ambispective study. Prostate Int. 2024;12:128\u201333. https:\/\/doi.org\/10.1016\/j.prnil.2024.03.005.","journal-title":"Prostate Int"},{"key":"9617_CR8","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1053\/j.semnuclmed.2021.11.013","volume":"52","author":"A Daryanani","year":"2022","unstructured":"Daryanani A, Turkbey B. Recent Advancements in CT and MR Imaging of Prostate Cancer. Semin Nucl Med. 2022;52:365\u201373. https:\/\/doi.org\/10.1053\/j.semnuclmed.2021.11.013.","journal-title":"Semin Nucl Med"},{"key":"9617_CR9","doi-asserted-by":"publisher","first-page":"5740","DOI":"10.1038\/s41598-024-56405-7","volume":"14","author":"H Zheng","year":"2024","unstructured":"Zheng H, Hung ALY, Miao Q, Song W, Scalzo F, Raman SS, et al. AtPCa-Net: anatomical-aware prostate cancer detection network on multi-parametric MRI. Sci Rep. 2024;14:5740. https:\/\/doi.org\/10.1038\/s41598-024-56405-7.","journal-title":"Sci Rep"},{"key":"9617_CR10","doi-asserted-by":"publisher","unstructured":"Zhang Z, Yang Q, Shiradkar R, Mirtti T, Azamat S, Xuan K, et al. A deep learning derived prostate zonal volume-based biomarker from T2\u2010weighted MRI to distinguish between prostate cancer and benign prostatic hyperplasia. Med Phys. 2025;52. https:\/\/doi.org\/10.1002\/mp.18053.","DOI":"10.1002\/mp.18053"},{"key":"9617_CR11","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.prnil.2016.09.002","volume":"4","author":"S Cabarkapa","year":"2016","unstructured":"Cabarkapa S, Perera M, McGrath S, Lawrentschuk N. Prostate cancer screening with prostate-specific antigen: A guide to the guidelines. Prostate Int. 2016;4:125\u20139. https:\/\/doi.org\/10.1016\/j.prnil.2016.09.002.","journal-title":"Prostate Int"},{"key":"9617_CR12","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1056\/NEJMcp1103642","volume":"365","author":"RM Hoffman","year":"2011","unstructured":"Hoffman RM. Screening for Prostate Cancer. N Engl J Med. 2011;365:2013\u20139. https:\/\/doi.org\/10.1056\/NEJMcp1103642.","journal-title":"N Engl J Med"},{"key":"9617_CR13","doi-asserted-by":"publisher","first-page":"5225","DOI":"10.2147\/CMAR.S250829","volume":"12","author":"CJ McNally","year":"2020","unstructured":"McNally CJ, Ruddock MW, Moore T, McKenna DJ. Biomarkers That Differentiate Benign Prostatic Hyperplasia from Prostate Cancer: A Literature Review. Cancer Manag Res. 2020;12:5225\u201341. https:\/\/doi.org\/10.2147\/CMAR.S250829.","journal-title":"Cancer Manag Res"},{"key":"9617_CR14","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1056\/NEJM198710083171501","volume":"317","author":"TA Stamey","year":"1987","unstructured":"Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate. N Engl J Med. 1987;317:909\u201316. https:\/\/doi.org\/10.1056\/NEJM198710083171501.","journal-title":"N Engl J Med"},{"key":"9617_CR15","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1056\/NEJMoa031918","volume":"350","author":"IM Thompson","year":"2004","unstructured":"Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level\u2009\u2264\u20094.0 ng per Milliliter. N Engl J Med. 2004;350:2239\u201346. https:\/\/doi.org\/10.1056\/NEJMoa031918.","journal-title":"N Engl J Med"},{"key":"9617_CR16","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1093\/jnci\/95.14.1027","volume":"95","author":"I Thompson","year":"2003","unstructured":"Thompson I, Leach RJ, Pollock BH, Naylor SL. Prostate Cancer and Prostate-Specific Antigen: The More We Know, the Less We Understand. JNCI J Natl Cancer Inst. 2003;95:1027\u20138. https:\/\/doi.org\/10.1093\/jnci\/95.14.1027.","journal-title":"JNCI J Natl Cancer Inst"},{"key":"9617_CR17","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1093\/jnci\/95.14.1044","volume":"95","author":"SD Cramer","year":"2003","unstructured":"Cramer SD, Chang B-L, Rao A, Hawkins GA, Zheng SL, Wade WN, et al. Association Between Genetic Polymorphisms in the Prostate-Specific Antigen Gene Promoter and Serum Prostate-Specific Antigen Levels. JNCI J Natl Cancer Inst. 2003;95:1044\u201353. https:\/\/doi.org\/10.1093\/jnci\/95.14.1044.","journal-title":"JNCI J Natl Cancer Inst"},{"key":"9617_CR18","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41391-022-00613-7","volume":"26","author":"M Barlow","year":"2023","unstructured":"Barlow M, Down L, Mounce LTA, Merriel SWD, Watson J, Martins T, et al. Ethnic differences in prostate-specific antigen levels in men without prostate cancer: a systematic review. Prostate Cancer Prostatic Dis. 2023;26:249\u201356. https:\/\/doi.org\/10.1038\/s41391-022-00613-7.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"9617_CR19","unstructured":"David MK, Leslie SW. Prostate specific antigen. StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2026 Jan.; 2024 [cited 2026 Mar 23]. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK557495\/. Accessed 23 Mar 2026."},{"key":"9617_CR20","doi-asserted-by":"publisher","unstructured":"Das L. Comprehensive Biochemical Insights into Prostate-Specific Antigen: From Biomarker to Functional Mediator in Prostate Cancer Pathophysiology. Anticancer Agents Med Chem. 2026;26. https:\/\/doi.org\/10.2174\/0118715206420493251029064813.","DOI":"10.2174\/0118715206420493251029064813"},{"key":"9617_CR21","first-page":"343","volume":"2","author":"Y-Q Huang","year":"2014","unstructured":"Huang Y-Q, Sun T, Zhong W-D, Wu C-L. Clinical performance of serum [-2]proPSA derivatives, %p2PSA and PHI, in the detection and management of prostate cancer. Am J Clin Exp Urol. 2014;2:343\u201350.","journal-title":"Am J Clin Exp Urol"},{"key":"9617_CR22","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3390\/diseases13060167","volume":"13","author":"Z Dushimova","year":"2025","unstructured":"Dushimova Z, Iztleuov Y, Chingayeva G, Shepetov A, Mustapayeva N, Shatkovskaya O, et al. Overdiagnosis and Overtreatment in Prostate Cancer. Diseases. 2025;13:167. https:\/\/doi.org\/10.3390\/diseases13060167.","journal-title":"Diseases"},{"key":"9617_CR23","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1056\/NEJMsb1616281","volume":"376","author":"PF Pinsky","year":"2017","unstructured":"Pinsky PF, Prorok PC, Kramer BS. Prostate Cancer Screening \u2014 A Perspective on the Current State of the Evidence. N Engl J Med. 2017;376:1285\u20139. https:\/\/doi.org\/10.1056\/NEJMsb1616281.","journal-title":"N Engl J Med"},{"key":"9617_CR24","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1038\/s41591-023-02277-9","volume":"29","author":"L Kachuri","year":"2023","unstructured":"Kachuri L, Hoffmann TJ, Jiang Y, Berndt SI, Shelley JP, Schaffer KR, et al. Genetically adjusted PSA levels for prostate cancer screening. Nat Med. 2023;29:1412\u201323. https:\/\/doi.org\/10.1038\/s41591-023-02277-9.","journal-title":"Nat Med"},{"key":"9617_CR25","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ejca.2022.12.017","volume":"181","author":"CD Fankhauser","year":"2023","unstructured":"Fankhauser CD, Parry MG, Ali A, Cowling TE, Nossiter J, Sujenthiran A, et al. A low prostate specific antigen predicts a worse outcome in high but not in low\/intermediate-grade prostate cancer. Eur J Cancer. 2023;181:70\u20138. https:\/\/doi.org\/10.1016\/j.ejca.2022.12.017.","journal-title":"Eur J Cancer"},{"key":"9617_CR26","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1093\/jnci\/djp122","volume":"101","author":"MR Cooperberg","year":"2009","unstructured":"Cooperberg MR, Broering JM, Carroll PR. Risk Assessment for Prostate Cancer Metastasis and Mortality at the Time of Diagnosis. JNCI: J Natl Cancer Inst. 2009;101:878\u201387. https:\/\/doi.org\/10.1093\/jnci\/djp122.","journal-title":"JNCI: J Natl Cancer Inst"},{"key":"9617_CR27","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.eururo.2018.01.043","volume":"74","author":"BA Mahal","year":"2018","unstructured":"Mahal BA, Yang DD, Wang NQ, Alshalalfa M, Davicioni E, Choeurng V, et al. Clinical and Genomic Characterization of Low\u2013Prostate-specific Antigen, High-grade Prostate Cancer. Eur Urol. 2018;74:146\u201354. https:\/\/doi.org\/10.1016\/j.eururo.2018.01.043.","journal-title":"Eur Urol"},{"key":"9617_CR28","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1590\/s1677-5538.ibju.2018.0143","volume":"45","author":"H Iwamoto","year":"2019","unstructured":"Iwamoto H, Izumi K, Kadono Y, Mizokami A. Prognosis of patients with prostate cancer and middle range prostate - specific antigen levels of 20\u2013100 ng \/ mL. Int braz j urol. 2019;45:61\u20137. https:\/\/doi.org\/10.1590\/s1677-5538.ibju.2018.0143.","journal-title":"Int braz j urol"},{"key":"9617_CR29","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.juro.2017.11.095","volume":"199","author":"MG Sanda","year":"2018","unstructured":"Sanda MG, Cadeddu JA, Kirkby E, Chen RC, Crispino T, Fontanarosa J, et al. Clinically Localized Prostate Cancer: AUA\/ASTRO\/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options. J Urol. 2018;199:683\u201390. https:\/\/doi.org\/10.1016\/j.juro.2017.11.095.","journal-title":"J Urol"},{"key":"9617_CR30","doi-asserted-by":"publisher","first-page":"479","DOI":"10.6004\/jnccn.2019.0023","volume":"17","author":"JL Mohler","year":"2019","unstructured":"Mohler JL, Antonarakis ES, Armstrong AJ, D\u2019Amico AV, Davis BJ, Dorff T, et al. Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019;17:479\u2013505. https:\/\/doi.org\/10.6004\/jnccn.2019.0023.","journal-title":"J Natl Compr Canc Netw"},{"key":"9617_CR31","doi-asserted-by":"publisher","unstructured":"Catalona WJ. Prostate Cancer Screening. Med Clin North Am. 2018;102:199\u2013214. https:\/\/doi.org\/10.1016\/j.mcna.2017.11.001.","DOI":"10.1016\/j.mcna.2017.11.001"},{"key":"9617_CR32","doi-asserted-by":"publisher","first-page":"5810","DOI":"10.1038\/s41598-024-55859-z","volume":"14","author":"PW McLaughlin","year":"2024","unstructured":"McLaughlin PW, Cousins MM, Tsodikov A, Soni PD, Crook JM. Mortality reduction and cumulative excess incidence (CEI) in the prostate-specific antigen (PSA) screening era. Sci Rep. 2024;14:5810. https:\/\/doi.org\/10.1038\/s41598-024-55859-z.","journal-title":"Sci Rep"},{"key":"9617_CR33","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1002\/cncr.34337","volume":"128","author":"DA Nnate","year":"2022","unstructured":"Nnate DA, Ball J. Current prostate cancer screening and treatment strategies may not support a holistic nationwide program. Cancer. 2022;128:2858\u201364. https:\/\/doi.org\/10.1002\/cncr.34337.","journal-title":"Cancer"},{"key":"9617_CR34","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.euf.2017.02.017","volume":"4","author":"P-J Lamy","year":"2018","unstructured":"Lamy P-J, Allory Y, Gauchez A-S, Asselain B, Beuzeboc P, de Cremoux P, et al. Prognostic Biomarkers Used for Localised Prostate Cancer Management: A Systematic Review. Eur Urol Focus. 2018;4:790\u2013803. https:\/\/doi.org\/10.1016\/j.euf.2017.02.017.","journal-title":"Eur Urol Focus"},{"key":"9617_CR35","doi-asserted-by":"publisher","first-page":"806","DOI":"10.3390\/diagnostics10100806","volume":"10","author":"VC Munteanu","year":"2020","unstructured":"Munteanu VC, Munteanu RA, Gulei D, Schitcu VH, Petrut B, Berindan Neagoe I, et al. PSA Based Biomarkers, Imagistic Techniques and Combined Tests for a Better Diagnostic of Localized Prostate Cancer. Diagnostics. 2020;10:806. https:\/\/doi.org\/10.3390\/diagnostics10100806.","journal-title":"Diagnostics"},{"key":"9617_CR36","doi-asserted-by":"publisher","unstructured":"Juan J, A D-R, E E E, Fabuel del AMM, Ramos de TM. -2proPSA and Prostate Health Index Usefulness for the Diagnosis of Prostate Cancer for PSA Range between 3 and 10 ng\/ml. Int Archives Urol Complications. 2018;4. https:\/\/doi.org\/10.23937\/2469-5742\/1510041.","DOI":"10.23937\/2469-5742\/1510041"},{"key":"9617_CR37","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1177\/1756287213513488","volume":"6","author":"S Loeb","year":"2014","unstructured":"Loeb S, Catalona WJ. The Prostate Health Index: a new test for the detection of prostate cancer. Ther Adv Urol. 2014;6:74\u20137. https:\/\/doi.org\/10.1177\/1756287213513488.","journal-title":"Ther Adv Urol"},{"key":"9617_CR38","doi-asserted-by":"publisher","first-page":"66","DOI":"10.5534\/wjmh.210076","volume":"40","author":"TA Narain","year":"2022","unstructured":"Narain TA, Sooriakumaran P. Beyond Prostate Specific Antigen: New Prostate Cancer Screening Options. World J Mens Health. 2022;40:66. https:\/\/doi.org\/10.5534\/wjmh.210076.","journal-title":"World J Mens Health"},{"key":"9617_CR39","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.juro.2015.01.091","volume":"194","author":"C de la Calle","year":"2015","unstructured":"de la Calle C, Patil D, Wei JT, Scherr DS, Sokoll L, Chan DW, et al. Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Na\u00efve Men. J Urol. 2015;194:65\u201372. https:\/\/doi.org\/10.1016\/j.juro.2015.01.091.","journal-title":"J Urol"},{"key":"9617_CR40","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.3390\/ijms21041184","volume":"21","author":"M Ferro","year":"2020","unstructured":"Ferro M, De Cobelli O, Lucarelli G, Porreca A, Busetto GM, Cantiello F, et al. Beyond PSA: The Role of Prostate Health Index (phi). Int J Mol Sci. 2020;21:1184. https:\/\/doi.org\/10.3390\/ijms21041184.","journal-title":"Int J Mol Sci"},{"key":"9617_CR41","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.6004\/jnccn.2018.7055","volume":"16","author":"G Olleik","year":"2018","unstructured":"Olleik G, Kassouf W, Aprikian A, Hu J, Vanhuyse M, Cury F, et al. Evaluation of New Tests and Interventions for Prostate Cancer Management: A Systematic Review. J Natl Compr Canc Netw. 2018;16:1340\u201351. https:\/\/doi.org\/10.6004\/jnccn.2018.7055.","journal-title":"J Natl Compr Canc Netw"},{"key":"9617_CR42","doi-asserted-by":"publisher","unstructured":"Park H, Lee SW, Song G, Kang TW, Jung JH, Chung HC, et al. Diagnostic Performance of %[-2]proPSA and Prostate Health Index for Prostate Cancer: Prospective, Multi-institutional Study. J Korean Med Sci. 2018;33. https:\/\/doi.org\/10.3346\/jkms.2018.33.e94.","DOI":"10.3346\/jkms.2018.33.e94"},{"key":"9617_CR43","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.prnil.2025.08.004","volume":"13","author":"K Oshinomi","year":"2025","unstructured":"Oshinomi K, Kikuchi S, Kishi H, Hayashi A, Okada S, Kurokawa M, et al. Utility of the prostate health index density for detecting clinically significant prostate cancer in patients with negative magnetic resonance imaging findings. Prostate Int. 2025;13:271\u20135. https:\/\/doi.org\/10.1016\/j.prnil.2025.08.004.","journal-title":"Prostate Int"},{"key":"9617_CR44","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1158\/1055-9965.EPI-19-1560","volume":"29","author":"BF Darst","year":"2020","unstructured":"Darst BF, Chou A, Wan P, Pooler L, Sheng X, Vertosick EA, et al. The Four-Kallikrein Panel Is Effective in Identifying Aggressive Prostate Cancer in a Multiethnic Population. Cancer Epidemiol Biomarkers Prev. 2020;29:1381\u20138. https:\/\/doi.org\/10.1158\/1055-9965.EPI-19-1560.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"9617_CR45","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/pros.23495","volume":"78","author":"MA Maccini","year":"2018","unstructured":"Maccini MA, Westfall NJ, Van Bokhoven A, Lucia MS, Poage W, Maroni PD, et al. The effect of digital rectal exam on the 4Kscore for aggressive prostate cancer. Prostate. 2018;78:506\u201311. https:\/\/doi.org\/10.1002\/pros.23495.","journal-title":"Prostate"},{"key":"9617_CR46","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.eururo.2015.04.028","volume":"69","author":"K Braun","year":"2016","unstructured":"Braun K, Sjoberg DD, Vickers AJ, Lilja H, Bjartell AS. A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort. Eur Urol. 2016;69:505\u201311. https:\/\/doi.org\/10.1016\/j.eururo.2015.04.028.","journal-title":"Eur Urol"},{"key":"9617_CR47","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.clgc.2016.12.022","volume":"15","author":"GI Russo","year":"2017","unstructured":"Russo GI, Regis F, Castelli T, Favilla V, Privitera S, Giardina R, et al. A Systematic Review and Meta-analysis of the Diagnostic Accuracy of Prostate Health Index and 4-Kallikrein Panel Score in Predicting Overall and High-grade Prostate Cancer. Clin Genitourin Cancer. 2017;15:429\u2013e4391. https:\/\/doi.org\/10.1016\/j.clgc.2016.12.022.","journal-title":"Clin Genitourin Cancer"},{"key":"9617_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4111\/icu.20200395","volume":"62","author":"JH Kim","year":"2021","unstructured":"Kim JH, Hong SK. Clinical utility of current biomarkers for prostate cancer detection. Investig Clin Urol. 2021;62:1. https:\/\/doi.org\/10.4111\/icu.20200395.","journal-title":"Investig Clin Urol"},{"key":"9617_CR49","doi-asserted-by":"publisher","first-page":"101042831879925","DOI":"10.1177\/1010428318799255","volume":"40","author":"A Carneiro","year":"2018","unstructured":"Carneiro A, Priante Kayano P, Gomes Barbosa \u00c1R, Langer Wroclawski M, Ko Chen C, Cavlini GC, et al. Are localized prostate cancer biomarkers useful in the clinical practice? Tumor Biology. 2018;40:101042831879925. https:\/\/doi.org\/10.1177\/1010428318799255.","journal-title":"Tumor Biology"},{"key":"9617_CR50","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.eururo.2014.10.021","volume":"68","author":"DJ Parekh","year":"2015","unstructured":"Parekh DJ, Punnen S, Sjoberg DD, Asroff SW, Bailen JL, Cochran JS, et al. A Multi-institutional Prospective Trial in the USA Confirms that the 4Kscore Accurately Identifies Men with High-grade Prostate Cancer. Eur Urol. 2015;68:464\u201370. https:\/\/doi.org\/10.1016\/j.eururo.2014.10.021.","journal-title":"Eur Urol"},{"key":"9617_CR51","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.21037\/tau-20-1151","volume":"10","author":"NW Eyrich","year":"2021","unstructured":"Eyrich NW, Morgan TM, Tosoian JJ. Biomarkers for detection of clinically significant prostate cancer: contemporary clinical data and future directions. Transl Androl Urol. 2021;10:3091\u2013103. https:\/\/doi.org\/10.21037\/tau-20-1151.","journal-title":"Transl Androl Urol"},{"key":"9617_CR52","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.3349\/ymj.2013.54.5.1202","volume":"54","author":"YM Kim","year":"2013","unstructured":"Kim YM, Park S, Kim J, Park S, Lee JH, Ryu DS, et al. Role of Prostate Volume in the Early Detection of Prostate Cancer in a Cohort with Slowly Increasing Prostate Specific Antigen. Yonsei Med J. 2013;54:1202. https:\/\/doi.org\/10.3349\/ymj.2013.54.5.1202.","journal-title":"Yonsei Med J"},{"key":"9617_CR53","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/aja.2013.11","volume":"15","author":"P Tang","year":"2013","unstructured":"Tang P, Jin X-L, Uhlman M, Lin Y-R, Deng X-R, Wang B, et al. Prostate volume as an independent predictor of prostate cancer in men with PSA of 10\u201350 ng ml\u2009\u2013\u20091. Asian J Androl. 2013;15:409\u201312. https:\/\/doi.org\/10.1038\/aja.2013.11.","journal-title":"Asian J Androl"},{"key":"9617_CR54","doi-asserted-by":"publisher","DOI":"10.2147\/RRU.S331506","author":"JR Yamashiro","year":"2021","unstructured":"Yamashiro JR, de Riese WT. Res Rep Urol. 2021;13:749\u201357. https:\/\/doi.org\/10.2147\/RRU.S331506. Any Correlation Between Prostate Volume and Incidence of Prostate Cancer: A Review of Reported Data for the Last Thirty Years."},{"key":"9617_CR55","doi-asserted-by":"publisher","first-page":"34","DOI":"10.2174\/1874091X01509010034","volume":"09","author":"J Coric","year":"2015","unstructured":"Coric J, Mujic J, Kucukalic E, Ler D. Prostate-Specific Antigen (PSA) and Prostate Volume: Better Predictor of Prostate Cancer for Bosnian and Herzegovina Men. Open Biochem J. 2015;09:34\u20136. https:\/\/doi.org\/10.2174\/1874091X01509010034.","journal-title":"Open Biochem J"},{"key":"9617_CR56","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1080\/13685538.2019.1578741","volume":"23","author":"A Erdogan","year":"2020","unstructured":"Erdogan A, Polat S, Keskin E, Turan A. Is prostate volume better than PSA density and free\/total PSA ratio in predicting prostate cancer in patients with PSA 2.5\u201310 ng\/mL and 10.1\u201330 ng\/mL? Aging Male. 2020;23:59\u201365. https:\/\/doi.org\/10.1080\/13685538.2019.1578741.","journal-title":"Aging Male"},{"key":"9617_CR57","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S0302-2838(03)00384-1","volume":"44","author":"CA Mochtar","year":"2003","unstructured":"Mochtar CA, Kiemeney LALM, van Riemsdijk MM, Barnett GS, Laguna MP, Debruyne FMJ, et al. Prostate-Specific Antigen as an Estimator of Prostate Volume in the Management of Patients with Symptomatic Benign Prostatic Hyperplasia. Eur Urol. 2003;44:695\u2013700. https:\/\/doi.org\/10.1016\/S0302-2838(03)00384-1.","journal-title":"Eur Urol"},{"key":"9617_CR58","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12301-023-00335-9","volume":"29","author":"C Aphinives","year":"2023","unstructured":"Aphinives C, Nawapun S, Tungnithiboon C. Diagnostic accuracy of MRI-based PSA density for detection of prostate cancer among the Thai population. Afr J Urol. 2023;29:4. https:\/\/doi.org\/10.1186\/s12301-023-00335-9.","journal-title":"Afr J Urol"},{"key":"9617_CR59","doi-asserted-by":"publisher","unstructured":"Bruno SM, Falagario UG, d\u2019Altilia N, Recchia M, Mancini V, Selvaggio O, et al. PSA Density Help to Identify Patients With Elevated PSA Due to Prostate Cancer Rather Than Intraprostatic Inflammation: A Prospective Single Center Study. Front Oncol. 2021;11. https:\/\/doi.org\/10.3389\/fonc.2021.693684.","DOI":"10.3389\/fonc.2021.693684"},{"key":"9617_CR60","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1055\/s-0040-1714195","volume":"12","author":"CK Nath","year":"2020","unstructured":"Nath CK, Barman B, Phukan P, Sailo SL, Dey B, Nath I, et al. Prostate-Specific Antigen Density: A Measurement to Differentiate Benign Hypertrophy of Prostate from Prostate Carcinoma. J Lab Physicians. 2020;12:44\u20138. https:\/\/doi.org\/10.1055\/s-0040-1714195.","journal-title":"J Lab Physicians"},{"key":"9617_CR61","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.45782","author":"O Feyisetan","year":"2023","unstructured":"Feyisetan O, Ezenwa V, Ramadhan M, Al-Hadeyah M, Johnson O, Hayat JN, et al. The Predictive Value of Prostate-Specific Antigen Density: A Retrospective Analysis of Likert 3 Multiparametric MRI of the Prostate. Cureus. 2023. https:\/\/doi.org\/10.7759\/cureus.45782.","journal-title":"Cureus"},{"key":"9617_CR62","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.euf.2025.06.008","volume":"11","author":"L Bj\u00f6rnebo","year":"2025","unstructured":"Bj\u00f6rnebo L, Discacciati A, Abbadi A, Falagario UG, Engel JC, Vigneswaran HT, et al. Prostate-specific Antigen Density as a Selection Tool Before Magnetic Resonance Imaging in Prostate Cancer Screening: An Analysis from the STHLM3MRI Randomized Clinical Trial. Eur Urol Focus. 2025;11:855\u201362. https:\/\/doi.org\/10.1016\/j.euf.2025.06.008.","journal-title":"Eur Urol Focus"},{"key":"9617_CR63","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0022-5347(17)37393-7","volume":"147","author":"MC Benson","year":"1992","unstructured":"Benson MC, Seong Whang I, Pantuck A, Ring K, Kaplan SA, Olsson CA, et al. Prostate Specific Antigen Density: A Means of Distinguishing Benign Prostatic Hypertrophy and Prostate Cancer. J Urol. 1992;147:815\u20136. https:\/\/doi.org\/10.1016\/S0022-5347(17)37393-7.","journal-title":"J Urol"},{"key":"9617_CR64","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S0094-0143(21)00918-6","volume":"20","author":"E Seaman","year":"1993","unstructured":"Seaman E, Whang M, Olsson CA, Katz A, Cooner WH, Benson MC, PSA DENSITY (PSAD). Urol Clin North Am. 1993;20:653\u201363. https:\/\/doi.org\/10.1016\/S0094-0143(21)00918-6.","journal-title":"Urol Clin North Am"},{"key":"9617_CR65","doi-asserted-by":"publisher","unstructured":"Stephan C, Stroebel G, Heinau M, Lenz A, Roemer A, Lein M, et al. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng\/mL. Cancer. 2005;104:993\u20131003.https:\/\/doi.org\/10.1002\/cncr.21267","DOI":"10.1002\/cncr.21267"},{"key":"9617_CR66","doi-asserted-by":"publisher","first-page":"20015","DOI":"10.1038\/s41598-020-76786-9","volume":"10","author":"I Yusim","year":"2020","unstructured":"Yusim I, Krenawi M, Mazor E, Novack V, Mabjeesh NJ. The use of prostate specific antigen density to predict clinically significant prostate cancer. Sci Rep. 2020;10:20015. https:\/\/doi.org\/10.1038\/s41598-020-76786-9.","journal-title":"Sci Rep"},{"key":"9617_CR67","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1002\/1097-0142(19940915)74:6<1667::AID-CNCR2820740605>3.0.CO;2-2","volume":"74","author":"MC Benson","year":"1994","unstructured":"Benson MC, Olsson CA. Prostate specific antigen and prostate specific antigen density. Roles in patient evaluation and management. Cancer. 1994;74:1667\u201373.","journal-title":"Cancer"},{"key":"9617_CR68","doi-asserted-by":"publisher","first-page":"502","DOI":"10.21037\/tcr-22-1855","volume":"12","author":"DH Park","year":"2023","unstructured":"Park DH, Yu JH. Prostate-specific antigen density as the best predictor of low- to intermediate-risk prostate cancer: a cohort study. Transl Cancer Res. 2023;12:502\u201314. https:\/\/doi.org\/10.21037\/tcr-22-1855.","journal-title":"Transl Cancer Res"},{"key":"9617_CR69","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1177\/20514158211059057","volume":"16","author":"A Lophatananon","year":"2023","unstructured":"Lophatananon A, Light A, Burns-Cox N, Maccormick A, John J, Otti V, et al. Re-evaluating the diagnostic efficacy of PSA as a referral test to detect clinically significant prostate cancer in contemporary MRI-based image-guided biopsy pathways. J Clin Urol. 2023;16:264\u201373. https:\/\/doi.org\/10.1177\/20514158211059057.","journal-title":"J Clin Urol"},{"key":"9617_CR70","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1002\/pros.24757","volume":"84","author":"K Malshy","year":"2024","unstructured":"Malshy K, Ochsner A, Homer A, Allu S, Passarelli N, Sojka A, et al. Consistent predictive ability of prostate-specific antigen density prediction model for clinically significant prostate cancer across age strata. Prostate. 2024;84:1209\u201317. https:\/\/doi.org\/10.1002\/pros.24757.","journal-title":"Prostate"},{"key":"9617_CR71","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1590\/s1677-5538.ibju.2017.0506","volume":"44","author":"HAS Castro","year":"2018","unstructured":"Castro HAS, Iared W, Santos JEM, Solha RS, Shigueoka DC, Ajzen SA. Impact of PSA density of transition zone as a potential parameter in reducing the number of unnecessary prostate biopsies in patients with PSA levels between 2.6 and 10.0 ng\/mL. Int braz j urol. 2018;44:709\u201316. https:\/\/doi.org\/10.1590\/s1677-5538.ibju.2017.0506.","journal-title":"Int braz j urol"},{"key":"9617_CR72","doi-asserted-by":"publisher","first-page":"e0218645","DOI":"10.1371\/journal.pone.0218645","volume":"14","author":"S Zheng","year":"2019","unstructured":"Zheng S, Jiang S, Chen Z, Huang Z, Shi W, Liu B, et al. The roles of MRI-based prostate volume and associated zone-adjusted prostate-specific antigen concentrations in predicting prostate cancer and high-risk prostate cancer. PLoS ONE. 2019;14:e0218645. https:\/\/doi.org\/10.1371\/journal.pone.0218645.","journal-title":"PLoS ONE"},{"key":"9617_CR73","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/S0022-5347(01)64961-9","volume":"157","author":"AR Zlotta","year":"1997","unstructured":"Zlotta AR, Djavan B, Marberger M, Schulman CC. Prostate Specific Antigen Density of the Transition Zone: A New Effective Parameter for Prostate Cancer Prediction. J Urol. 1997;157:1315\u201321. https:\/\/doi.org\/10.1016\/S0022-5347(01)64961-9.","journal-title":"J Urol"},{"key":"9617_CR74","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/1097-0142(20000815)89:4<842::AID-CNCR17>3.0.CO;2-9","volume":"89","author":"E Kikuchi","year":"2000","unstructured":"Kikuchi E, Nakashima J, Ishibashi M, Ohigashi T, Asakura H, Tachibana M, et al. Prostate specific antigen adjusted for transition zone volume. Cancer. 2000;89:842\u20139.","journal-title":"Cancer"},{"key":"9617_CR75","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.eururo.2003.07.001","volume":"45","author":"M Ohi","year":"2004","unstructured":"Ohi M. Diagnostic Significance of PSA Density Adjusted by Transition Zone Volume in Males with PSA Levels between 2 and 4ng\/ml. Eur Urol. 2004;45:92\u20137. https:\/\/doi.org\/10.1016\/j.eururo.2003.07.001.","journal-title":"Eur Urol"},{"key":"9617_CR76","doi-asserted-by":"publisher","first-page":"3722","DOI":"10.1007\/s00261-024-04301-z","volume":"49","author":"S Kuanar","year":"2024","unstructured":"Kuanar S, Cai J, Nakai H, Nagayama H, Takahashi H, LeGout J, et al. Transition-zone PSA-density calculated from MRI deep learning prostate zonal segmentation model for prediction of clinically significant prostate cancer. Abdom Radiol. 2024;49:3722\u201334. https:\/\/doi.org\/10.1007\/s00261-024-04301-z.","journal-title":"Abdom Radiol"},{"key":"9617_CR77","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/S0022-5347(01)62911-2","volume":"160","author":"B DJAVAN","year":"1998","unstructured":"DJAVAN B, ZLOTTA AR, BYTTEBIER G, SHARIAT S, OMAR M, SCHULMAN CC, PROSTATE SPECIFIC ANTIGEN DENSITY OF THE TRANSITION ZONE FOR EARLY DETECTION OF PROSTATE CANCER, et al. J Urol. 1998;160:411\u20138. https:\/\/doi.org\/10.1016\/S0022-5347(01)62911-2.","journal-title":"J Urol"},{"key":"9617_CR78","doi-asserted-by":"publisher","first-page":"108660","DOI":"10.1016\/j.ejrad.2019.108660","volume":"120","author":"AF Schneider","year":"2019","unstructured":"Schneider AF, Stocker D, H\u00f6tker AM, Eberli D, Rupp NJ, Donati OF, et al. Comparison of PSA-density of the transition zone and whole gland for risk stratification of men with suspected prostate cancer: A retrospective MRI-cohort study. Eur J Radiol. 2019;120:108660. https:\/\/doi.org\/10.1016\/j.ejrad.2019.108660.","journal-title":"Eur J Radiol"},{"key":"9617_CR79","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/sj.pcan.4500957","volume":"10","author":"N Tanaka","year":"2007","unstructured":"Tanaka N, Fujimoto K, Chihara Y, Torimoto M, Hirao Y, Konishi N, et al. Prostatic volume and volume-adjusted prostate-specific antigen as predictive parameters for prostate cancer patients with intermediate PSA levels. Prostate Cancer Prostatic Dis. 2007;10:274\u20138. https:\/\/doi.org\/10.1038\/sj.pcan.4500957.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"9617_CR80","doi-asserted-by":"publisher","first-page":"32830","DOI":"10.1038\/s41598-025-18336-9","volume":"15","author":"C Wang","year":"2025","unstructured":"Wang C, Han J, Zhu W, Zheng B, Qiu Y. A nomogram using transition zone PSA density for detecting clinically significant prostate cancer in PI-RADS 3 lesions. Sci Rep. 2025;15:32830. https:\/\/doi.org\/10.1038\/s41598-025-18336-9.","journal-title":"Sci Rep"},{"key":"9617_CR81","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13244-026-02221-8","volume":"17","author":"J Shang","year":"2026","unstructured":"Shang J, Wu J, Deng R, Shang M, Wu P, Qiu J, et al. Artificial intelligence-derived transition zone PSA density as a triage tool to reduce unnecessary prostate systematic biopsies in MRI-negative men. Insights Imaging. 2026;17:40. https:\/\/doi.org\/10.1186\/s13244-026-02221-8.","journal-title":"Insights Imaging"},{"key":"9617_CR82","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.eururo.2004.10.009","volume":"47","author":"S S\u00f6zen","year":"2005","unstructured":"S\u00f6zen S, Eskicorapci S, K\u00fcpeli B, \u0130rkilata L, Altinel M, \u00d6zer G, et al. Complexed Prostate Specific Antigen Density is Better Than the Other PSA Derivatives for Detection of Prostate Cancer in Men with Total PSA between 2.5 and 20ng\/ml: Results of a Prospective Multicenter Study. Eur Urol. 2005;47:302\u20137. https:\/\/doi.org\/10.1016\/j.eururo.2004.10.009.","journal-title":"Eur Urol"},{"key":"9617_CR83","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/S0090-4295(02)01896-4","volume":"60","author":"B Djavan","year":"2002","unstructured":"Djavan B, Remzi M, Zlotta AR, Ravery V, Hammerer P, Reissigl A, et al. Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed\/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial. Urology. 2002;60:4\u20139. https:\/\/doi.org\/10.1016\/S0090-4295(02)01896-4.","journal-title":"Urology"},{"key":"9617_CR84","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/j.1464-410X.2004.04899.x","volume":"94","author":"JK Parsons","year":"2004","unstructured":"Parsons JK, Brawer MK, Cheli CD, Partin AW, Djavan R. Complexed prostate specific antigen (PSA) reduces unnecessary prostate biopsies in the 2.6\u20134.0\u2003ng\/mL range of total PSA. BJU Int. 2004;94:47\u201350. https:\/\/doi.org\/10.1111\/j.1464-410X.2004.04899.x.","journal-title":"BJU Int"},{"key":"9617_CR85","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S0090-4295(99)00149-1","volume":"54","author":"H Maeda","year":"1999","unstructured":"Maeda H, Arai Y, Aoki Y, Okubo K, Okada T, Maekawa S. Complexed prostate-specific antigen and its volume indexes in the detection of prostate cancer. Urology. 1999;54:225\u20138. https:\/\/doi.org\/10.1016\/S0090-4295(99)00149-1.","journal-title":"Urology"},{"key":"9617_CR86","doi-asserted-by":"publisher","first-page":"209","DOI":"10.6004\/jnccn.2004.0019","volume":"2","author":"Y Naya","year":"2004","unstructured":"Naya Y, Okihara K. Role of Complexed PSA in the Early Detection of Prostate Cancer. J Natl Compr Canc Netw. 2004;2:209\u201312. https:\/\/doi.org\/10.6004\/jnccn.2004.0019.","journal-title":"J Natl Compr Canc Netw"},{"key":"9617_CR87","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1093\/jnci\/djr028","volume":"103","author":"AJ Vickers","year":"2011","unstructured":"Vickers AJ, Till C, Tangen CM, Lilja H, Thompson IM. An Empirical Evaluation of Guidelines on Prostate-specific Antigen Velocity in Prostate Cancer Detection. JNCI: J Natl Cancer Inst. 2011;103:462\u20139. https:\/\/doi.org\/10.1093\/jnci\/djr028.","journal-title":"JNCI: J Natl Cancer Inst"},{"key":"9617_CR88","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.bjmsu.2011.08.006","volume":"5","author":"AJ Vickers","year":"2012","unstructured":"Vickers AJ, Brewster SF. PSA Velocity and Doubling Time in Diagnosis and Prognosis of Prostate Cancer. Br J Med Surg Urol. 2012;5:162\u20138. https:\/\/doi.org\/10.1016\/j.bjmsu.2011.08.006.","journal-title":"Br J Med Surg Urol"},{"key":"9617_CR89","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.clgc.2019.08.002","volume":"17","author":"MC Markowski","year":"2019","unstructured":"Markowski MC, Chen Y, Feng Z, Cullen J, Trock BJ, Suzman D, et al. PSA Doubling Time and Absolute PSA Predict Metastasis-free Survival in Men With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. Clin Genitourin Cancer. 2019;17:470\u2013e4751. https:\/\/doi.org\/10.1016\/j.clgc.2019.08.002.","journal-title":"Clin Genitourin Cancer"},{"key":"9617_CR90","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3892\/mco.2016.1116","volume":"6","author":"H Takeuchi","year":"2017","unstructured":"Takeuchi H, Ohori M, Tachibana M. Clinical significance of the prostate-specific antigen doubling time prior to and following radical prostatectomy to predict the outcome of prostate cancer. Mol Clin Oncol. 2017;6:249\u201354. https:\/\/doi.org\/10.3892\/mco.2016.1116.","journal-title":"Mol Clin Oncol"},{"key":"9617_CR91","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/sj.pcan.4500614","volume":"6","author":"RH Riffenburgh","year":"2003","unstructured":"Riffenburgh RH, Amling CL. Use of early PSA velocity to predict eventual abnormal PSA values in men at risk for prostate cancer. Prostate Cancer Prostatic Dis. 2003;6:39\u201344. https:\/\/doi.org\/10.1038\/sj.pcan.4500614.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"9617_CR92","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1093\/jnci\/djm171","volume":"99","author":"RD Etzioni","year":"2007","unstructured":"Etzioni RD, Ankerst DP, Weiss NS, Inoue LYT, Thompson IM. Is Prostate-Specific Antigen Velocity Useful in Early Detection of Prostate Cancer? A Critical Appraisal of the Evidence. JNCI J Natl Cancer Inst. 2007;99:1510\u20135. https:\/\/doi.org\/10.1093\/jnci\/djm171.","journal-title":"JNCI J Natl Cancer Inst"},{"key":"9617_CR93","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1002\/pros.23806","volume":"79","author":"F Li","year":"2019","unstructured":"Li F, Pascal LE, Stolz DB, Wang K, Zhou Y, Chen W, et al. E-cadherin is downregulated in benign prostatic hyperplasia and required for tight junction formation and permeability barrier in the prostatic epithelial cell monolayer. Prostate. 2019;79:1226\u201337. https:\/\/doi.org\/10.1002\/pros.23806.","journal-title":"Prostate"},{"key":"9617_CR94","first-page":"475","volume":"11","author":"EP DeAntoni","year":"1997","unstructured":"DeAntoni EP. Age-specific reference ranges for PSA in the detection of prostate cancer. Oncol (Williston Park). 1997;11:475\u201382. 485; discussion 485-6.","journal-title":"Oncol (Williston Park)"},{"key":"9617_CR95","doi-asserted-by":"publisher","unstructured":"MacKintosh FR, Sprenkle PC, Walter LC, Rawson L, Karnes RJ, Morrell CH, et al. Age and Prostate-Specific Antigen Level Prior to Diagnosis Predict Risk of Death from Prostate Cancer. Front Oncol. 2016;6. https:\/\/doi.org\/10.3389\/fonc.2016.00157.","DOI":"10.3389\/fonc.2016.00157"},{"key":"9617_CR96","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1056\/NEJM199608013350502","volume":"335","author":"TO Morgan","year":"1996","unstructured":"Morgan TO, Jacobsen SJ, McCarthy WF, Jacobson DJ, McLeod DG, Moul JW. Age-Specific Reference Ranges for Serum Prostate-Specific Antigen in Black Men. N Engl J Med. 1996;335:304\u201310. https:\/\/doi.org\/10.1056\/NEJM199608013350502.","journal-title":"N Engl J Med"},{"key":"9617_CR97","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/JU.0000000000003491","volume":"210","author":"JT Wei","year":"2023","unstructured":"Wei JT, Barocas D, Carlsson S, Coakley F, Eggener S, Etzioni R, et al. Early Detection of Prostate Cancer: AUA\/SUO Guideline Part I: Prostate Cancer Screening. J Urol. 2023;210:46\u201353. https:\/\/doi.org\/10.1097\/JU.0000000000003491.","journal-title":"J Urol"},{"key":"9617_CR98","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s10552-018-1014-3","volume":"29","author":"R Gilbert","year":"2018","unstructured":"Gilbert R, Tilling K, Martin RM, Lane JA, Davis M, Hamdy FC, et al. Developing new age-specific prostate-specific antigen thresholds for testing for prostate cancer. Cancer Causes Control. 2018;29:383\u20138. https:\/\/doi.org\/10.1007\/s10552-018-1014-3.","journal-title":"Cancer Causes Control"},{"key":"9617_CR99","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.euo.2024.11.010","volume":"8","author":"IO Ola","year":"2025","unstructured":"Ola IO, Talala K, Tammela T, Taari K, Murtola TJ, Kujala P, et al. Long-term Risk of Prostate Cancer Mortality Among Men with Baseline Prostate-specific Antigen Below 3 ng\/ml: Evidence from the Finnish Randomized Study of Screening for Prostate Cancer. Eur Urol Oncol. 2025;8:452\u20139. https:\/\/doi.org\/10.1016\/j.euo.2024.11.010.","journal-title":"Eur Urol Oncol"},{"key":"9617_CR100","doi-asserted-by":"publisher","unstructured":"Iheanacho CO, Odili VU, Enakirerhi GE, Isiwele EM, Essiet A, Pattern. Clinical Characteristics, and Impact of Family History on Prostate-Specific Antigen in Prostate Cancer: A Multicenter Study. Am J Mens Health. 2024;18. https:\/\/doi.org\/10.1177\/15579883241264949.","DOI":"10.1177\/15579883241264949"},{"key":"9617_CR101","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.3390\/cancers13153726","volume":"13","author":"A Ka\u0142u\u017ca","year":"2021","unstructured":"Ka\u0142u\u017ca A, Szczykutowicz J, Ferens-Sieczkowska M, Glycosylation. Rising Potential for Prostate Cancer Evaluation. Cancers (Basel). 2021;13:3726. https:\/\/doi.org\/10.3390\/cancers13153726.","journal-title":"Cancers (Basel)"},{"key":"9617_CR102","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1038\/s41388-023-02604-x","volume":"42","author":"E Scott","year":"2023","unstructured":"Scott E, Hodgson K, Calle B, Turner H, Cheung K, Bermudez A, et al. Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth. Oncogene. 2023;42:926\u201337. https:\/\/doi.org\/10.1038\/s41388-023-02604-x.","journal-title":"Oncogene"},{"key":"9617_CR103","doi-asserted-by":"publisher","first-page":"5570","DOI":"10.1021\/pr500575r","volume":"13","author":"E Song","year":"2014","unstructured":"Song E, Mayampurath A, Yu C-Y, Tang H, Mechref Y, Glycoproteomics. Identifying the Glycosylation of Prostate Specific Antigen at Normal and High Isoelectric Points by LC\u2013MS\/MS. J Proteome Res. 2014;13:5570\u201380. https:\/\/doi.org\/10.1021\/pr500575r.","journal-title":"J Proteome Res"},{"key":"9617_CR104","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/pros.2990270403","volume":"27","author":"A B\u00e9langer","year":"1995","unstructured":"B\u00e9langer A, Van Halbeek H, Graves HCB, Grandbois K, Stamey TA, Huang L, et al. Molecular mass and carbohydrate structure of prostate specific antigen: Studies for establishment of an international PSA standard. Prostate. 1995;27:187\u201397. https:\/\/doi.org\/10.1002\/pros.2990270403.","journal-title":"Prostate"},{"key":"9617_CR105","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1002\/pros.22826","volume":"74","author":"Z Chen","year":"2014","unstructured":"Chen Z, Gulzar ZG, St. Hill CA, Walcheck B, Brooks JD. Increased expression of GCNT1 is associated with altered O -glycosylation of PSA, PAP, and MUC1 in human prostate cancers. Prostate. 2014;74:1059\u201367. https:\/\/doi.org\/10.1002\/pros.22826.","journal-title":"Prostate"},{"key":"9617_CR106","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1093\/clinchem\/41.11.1567","volume":"41","author":"WM Zhang","year":"1995","unstructured":"Zhang WM, Leinonen J, Kalkkinen N, Dowell B, Stenman UH. Purification and characterization of different molecular forms of prostate-specific antigen in human seminal fluid. Clin Chem. 1995;41:1567\u201373.","journal-title":"Clin Chem"},{"key":"9617_CR107","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1093\/glycob\/cwg041","volume":"13","author":"R Peracaula","year":"2003","unstructured":"Peracaula R. Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins. Glycobiology. 2003;13:457\u201370. https:\/\/doi.org\/10.1093\/glycob\/cwg041.","journal-title":"Glycobiology"},{"key":"9617_CR108","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1021\/acs.jproteome.5b00362","volume":"14","author":"E Song","year":"2015","unstructured":"Song E, Hu Y, Hussein A, Yu C-Y, Tang H, Mechref Y. Characterization of the Glycosylation Site of Human PSA Prompted by Missense Mutation using LC\u2013MS\/MS. J Proteome Res. 2015;14:2872\u201383. https:\/\/doi.org\/10.1021\/acs.jproteome.5b00362.","journal-title":"J Proteome Res"},{"key":"9617_CR109","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S0304-4165(00)00182-3","volume":"1525","author":"T Okada","year":"2001","unstructured":"Okada T, Sato Y, Kobayashi N, Sumida K, Satomura S, Matsuura S, et al. Structural characteristics of the N-glycans of two isoforms of prostate-specific antigens purified from human seminal fluid. Biochim et Biophys Acta (BBA) - Gen Subj. 2001;1525:149\u201360. https:\/\/doi.org\/10.1016\/S0304-4165(00)00182-3.","journal-title":"Biochim et Biophys Acta (BBA) - Gen Subj"},{"key":"9617_CR110","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1093\/glycob\/10.2.173","volume":"10","author":"S Prakash","year":"2000","unstructured":"Prakash S. Glycotyping of prostate specific antigen. Glycobiology. 2000;10:173\u20136. https:\/\/doi.org\/10.1093\/glycob\/10.2.173.","journal-title":"Glycobiology"},{"key":"9617_CR111","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nrurol.2012.258","volume":"10","author":"S Gilgunn","year":"2013","unstructured":"Gilgunn S, Conroy PJ, Saldova R, Rudd PM, O\u2019Kennedy RJ. Aberrant PSA glycosylation\u2014a sweet predictor of prostate cancer. Nat Rev Urol. 2013;10:99\u2013107. https:\/\/doi.org\/10.1038\/nrurol.2012.258.","journal-title":"Nat Rev Urol"},{"key":"9617_CR112","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nrc3982","volume":"15","author":"SS Pinho","year":"2015","unstructured":"Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer. 2015;15:540\u201355. https:\/\/doi.org\/10.1038\/nrc3982.","journal-title":"Nat Rev Cancer"},{"key":"9617_CR113","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.7150\/thno.15226","volume":"6","author":"E Llop","year":"2016","unstructured":"Llop E, Ferrer-Batall\u00e9 M, Barrab\u00e9s S, Guerrero PE, Ram\u00edrez M, Saldova R, et al. Improvement of Prostate Cancer Diagnosis by Detecting PSA Glycosylation-Specific Changes. Theranostics. 2016;6:1190\u2013204. https:\/\/doi.org\/10.7150\/thno.15226.","journal-title":"Theranostics"},{"key":"9617_CR114","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/glycob\/cwh071","volume":"14","author":"C Ohyama","year":"2004","unstructured":"Ohyama C. Carbohydrate structure and differential binding of prostate specific antigen to Maackia amurensis lectin between prostate cancer and benign prostate hypertrophy. Glycobiology. 2004;14:671\u20139. https:\/\/doi.org\/10.1093\/glycob\/cwh071.","journal-title":"Glycobiology"},{"key":"9617_CR115","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/glycob\/cwq147","volume":"21","author":"R Saldova","year":"2011","unstructured":"Saldova R, Fan Y, Fitzpatrick JM, Watson RWG, Rudd PM. Core fucosylation and 2\u20133 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia. Glycobiology. 2011;21:195\u2013205. https:\/\/doi.org\/10.1093\/glycob\/cwq147.","journal-title":"Glycobiology"},{"key":"9617_CR116","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.1038\/s41598-020-59622-y","volume":"10","author":"H Ideo","year":"2020","unstructured":"Ideo H, Kondo J, Nomura T, Nonomura N, Inoue M, Amano J. Study of glycosylation of prostate-specific antigen secreted by cancer tissue-originated spheroids reveals new candidates for prostate cancer detection. Sci Rep. 2020;10:2708. https:\/\/doi.org\/10.1038\/s41598-020-59622-y.","journal-title":"Sci Rep"},{"key":"9617_CR117","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.aca.2016.06.043","volume":"934","author":"D Pihikova","year":"2016","unstructured":"Pihikova D, Kasak P, Kubanikova P, Sokol R, Tkac J. Aberrant sialylation of a prostate-specific antigen: Electrochemical label-free glycoprofiling in prostate cancer serum samples. Anal Chim Acta. 2016;934:72\u20139. https:\/\/doi.org\/10.1016\/j.aca.2016.06.043.","journal-title":"Anal Chim Acta"},{"key":"9617_CR118","doi-asserted-by":"publisher","first-page":"470","DOI":"10.3390\/ijms18020470","volume":"18","author":"T Ishikawa","year":"2017","unstructured":"Ishikawa T, Yoneyama T, Tobisawa Y, Hatakeyama S, Kurosawa T, Nakamura K, et al. An Automated Micro-Total Immunoassay System for Measuring Cancer-Associated \u03b12,3-linked Sialyl N-Glycan-Carrying Prostate-Specific Antigen May Improve the Accuracy of Prostate Cancer Diagnosis. Int J Mol Sci. 2017;18:470. https:\/\/doi.org\/10.3390\/ijms18020470.","journal-title":"Int J Mol Sci"},{"key":"9617_CR119","doi-asserted-by":"publisher","first-page":"18974","DOI":"10.1038\/s41598-020-75526-3","volume":"10","author":"A Gratac\u00f3s-Mulleras","year":"2020","unstructured":"Gratac\u00f3s-Mulleras A, Duran A, Asadi Shehni A, Ferrer-Batall\u00e9 M, Ram\u00edrez M, Comet J, et al. Characterisation of the main PSA glycoforms in aggressive prostate cancer. Sci Rep. 2020;10:18974. https:\/\/doi.org\/10.1038\/s41598-020-75526-3.","journal-title":"Sci Rep"},{"key":"9617_CR120","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/glycob\/cwm117","volume":"18","author":"M Tajiri","year":"2008","unstructured":"Tajiri M, Ohyama C, Wada Y. Oligosaccharide Profiles of the Prostate Specific Antigen in Free and Complexed Forms from the Prostate Cancer Patient Serum and in Seminal Plasma: a Glycopeptide Approach. Glycobiology. 2008;18:2\u20138. https:\/\/doi.org\/10.1093\/glycob\/cwm117.","journal-title":"Glycobiology"},{"key":"9617_CR121","doi-asserted-by":"publisher","first-page":"845","DOI":"10.3390\/ijms18040845","volume":"18","author":"M Ferrer-Batall\u00e9","year":"2017","unstructured":"Ferrer-Batall\u00e9 M, Llop E, Ram\u00edrez M, Aleixandre R, Saez M, Comet J, et al. Comparative Study of Blood-Based Biomarkers, \u03b12,3-Sialic Acid PSA and PHI, for High-Risk Prostate Cancer Detection. Int J Mol Sci. 2017;18:845. https:\/\/doi.org\/10.3390\/ijms18040845.","journal-title":"Int J Mol Sci"},{"key":"9617_CR122","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1021\/acs.analchem.7b04281","volume":"90","author":"GSM Kammeijer","year":"2018","unstructured":"Kammeijer GSM, Nouta J, de la Rosette JJMCH, de Reijke TM, Wuhrer M. An In-Depth Glycosylation Assay for Urinary Prostate-Specific Antigen. Anal Chem. 2018;90:4414\u201321. https:\/\/doi.org\/10.1021\/acs.analchem.7b04281.","journal-title":"Anal Chem"},{"key":"9617_CR123","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12014-019-9234-4","volume":"16","author":"C Wang","year":"2019","unstructured":"Wang C, H\u00f6ti N, Lih T-SM, Sokoll LJ, Zhang R, Zhang Z, et al. Development of a glycoproteomic strategy to detect more aggressive prostate cancer using lectin-immunoassays for serum fucosylated PSA. Clin Proteom. 2019;16:13. https:\/\/doi.org\/10.1186\/s12014-019-9234-4.","journal-title":"Clin Proteom"},{"key":"9617_CR124","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/s41416-021-01637-x","volume":"126","author":"K Hatano","year":"2022","unstructured":"Hatano K, Yoneyama T, Hatakeyama S, Tomiyama E, Tsuchiya M, Nishimoto M, et al. Simultaneous analysis of serum \u03b12,3-linked sialylation and core-type fucosylation of prostate-specific antigen for the detection of high-grade prostate cancer. Br J Cancer. 2022;126:764\u201370. https:\/\/doi.org\/10.1038\/s41416-021-01637-x.","journal-title":"Br J Cancer"},{"key":"9617_CR125","doi-asserted-by":"publisher","first-page":"20180077","DOI":"10.1098\/rsfs.2018.0077","volume":"9","author":"J Tkac","year":"2019","unstructured":"Tkac J, Gajdosova V, Hroncekova S, Bertok T, Hires M, Jane E, et al. Prostate-specific antigen glycoprofiling as diagnostic and prognostic biomarker of prostate cancer. Interface Focus. 2019;9:20180077. https:\/\/doi.org\/10.1098\/rsfs.2018.0077.","journal-title":"Interface Focus"},{"key":"9617_CR126","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S0009-9120(03)00050-X","volume":"36","author":"PS Basu","year":"2003","unstructured":"Basu PS, Majhi R, Batabyal SK. Lectin and serum-PSA interaction as a screening test for prostate cancer. Clin Biochem. 2003;36:373\u20136. https:\/\/doi.org\/10.1016\/S0009-9120(03)00050-X.","journal-title":"Clin Biochem"},{"key":"9617_CR127","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1002\/prca.201200134","volume":"7","author":"JO Nyalwidhe","year":"2013","unstructured":"Nyalwidhe JO, Betesh LR, Powers TW, Jones EE, White KY, Burch TC, et al. Increased bisecting <\u2009scp>N -acetylglucosamine and decreased branched chain glycans of <\u2009scp>N \u2010linked glycoproteins in expressed prostatic secretions associated with prostate cancer progression. Proteom Clin Appl. 2013;7:677\u201389. https:\/\/doi.org\/10.1002\/prca.201200134.","journal-title":"Proteom Clin Appl"},{"key":"9617_CR128","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.3390\/ijms20061389","volume":"20","author":"E Scott","year":"2019","unstructured":"Scott E, Munkley J. Glycans as Biomarkers in Prostate Cancer. Int J Mol Sci. 2019;20:1389. https:\/\/doi.org\/10.3390\/ijms20061389.","journal-title":"Int J Mol Sci"},{"key":"9617_CR129","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.bbrc.2020.03.168","volume":"527","author":"P-W Cheng","year":"2020","unstructured":"Cheng P-W, Davidson S, Bhat G. Markers of malignant prostate cancer cells: Golgi localization of \u03b1-mannosidase 1A at GM130-GRASP65 site and appearance of high mannose N-glycans on cell surface. Biochem Biophys Res Commun. 2020;527:406\u201310. https:\/\/doi.org\/10.1016\/j.bbrc.2020.03.168.","journal-title":"Biochem Biophys Res Commun"},{"key":"9617_CR130","doi-asserted-by":"publisher","first-page":"136519","DOI":"10.1016\/j.ijbiomac.2024.136519","volume":"281","author":"JM Sanji","year":"2024","unstructured":"Sanji JM, Gurav AS, Megalamani MJ, Vanti PH, Kurjogi G. Overexpression of sialyl Lewisa carrying mucin-type glycoprotein in prostate cancer cell line contributes to aggressiveness and metastasis. Int J Biol Macromol. 2024;281:136519. https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.136519.","journal-title":"Int J Biol Macromol"},{"key":"9617_CR131","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1111\/cas.14082","volume":"110","author":"T Yoneyama","year":"2019","unstructured":"Yoneyama T, Tobisawa Y, Kaneko T, Kaya T, Hatakeyama S, Mori K, et al. Clinical significance of the Lacdi\u2009<\u2009scp>NA\u2009c-glycosylated prostate\u2010specific antigen assay for prostate cancer detection. Cancer Sci. 2019;110:2573\u201389. https:\/\/doi.org\/10.1111\/cas.14082.","journal-title":"Cancer Sci"},{"key":"9617_CR132","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/nrc3678","volume":"14","author":"IG Mills","year":"2014","unstructured":"Mills IG. Maintaining and reprogramming genomic androgen receptor activity in prostate cancer. Nat Rev Cancer. 2014;14:187\u201398. https:\/\/doi.org\/10.1038\/nrc3678.","journal-title":"Nat Rev Cancer"},{"key":"9617_CR133","doi-asserted-by":"publisher","first-page":"34358","DOI":"10.18632\/oncotarget.6024","volume":"6","author":"J Munkley","year":"2015","unstructured":"Munkley J, Oltean S, Vod\u00e1k D, Wilson BT, Livermore KE, Zhou Y, et al. The androgen receptor controls expression of the cancer-associated sTn antigen and cell adhesion through induction of ST6GalNAc1 in prostate cancer. Oncotarget. 2015;6:34358\u201374. https:\/\/doi.org\/10.18632\/oncotarget.6024.","journal-title":"Oncotarget"},{"key":"9617_CR134","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/981627","volume":"2014","author":"K Hirano","year":"2014","unstructured":"Hirano K, Matsuda A, Shirai T, Furukawa K. Expression of LacdiNAc Groups on N-Glycans among Human Tumors Is Complex. Biomed Res Int. 2014;2014:1\u20137. https:\/\/doi.org\/10.1155\/2014\/981627.","journal-title":"Biomed Res Int"},{"key":"9617_CR135","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1021\/acs.analchem.8b04829","volume":"91","author":"Y Haga","year":"2019","unstructured":"Haga Y, Uemura M, Baba S, Inamura K, Takeuchi K, Nonomura N, et al. Identification of Multisialylated LacdiNAc Structures as Highly Prostate Cancer Specific Glycan Signatures on PSA. Anal Chem. 2019;91:2247\u201354. https:\/\/doi.org\/10.1021\/acs.analchem.8b04829.","journal-title":"Anal Chem"},{"key":"9617_CR136","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3390\/ijms18020261","volume":"18","author":"K Hagiwara","year":"2017","unstructured":"Hagiwara K, Tobisawa Y, Kaya T, Kaneko T, Hatakeyama S, Mori K, et al. Wisteria floribunda Agglutinin and Its Reactive-Glycan-Carrying Prostate-Specific Antigen as a Novel Diagnostic and Prognostic Marker of Prostate Cancer. Int J Mol Sci. 2017;18:261. https:\/\/doi.org\/10.3390\/ijms18020261.","journal-title":"Int J Mol Sci"},{"key":"9617_CR137","doi-asserted-by":"publisher","unstructured":"Yamashita K, Ohkura T, Umetsu K, Suzuki T. Purification and characterization of a Fuc alpha 1\u2013>2Gal beta 1\u2013> and GalNAc beta 1\u2013>-specific lectin in root tubers of Trichosanthes japonica. Journal of Biological Chemistry. 1992;267:25414\u201322. https:\/\/doi.org\/10.1016\/S0021-9258(19)74057-5","DOI":"10.1016\/S0021-9258(19)74057-5"},{"key":"9617_CR138","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1093\/glycob\/cwp197","volume":"20","author":"K Fukushima","year":"2010","unstructured":"Fukushima K, Satoh T, Baba S, Yamashita K. 1,2-Fucosylated and -N-acetylgalactosaminylated prostate-specific antigen as an efficient marker of prostatic cancer. Glycobiology. 2010;20:452\u201360. https:\/\/doi.org\/10.1093\/glycob\/cwp197.","journal-title":"Glycobiology"},{"key":"9617_CR139","doi-asserted-by":"publisher","first-page":"116156","DOI":"10.1016\/j.bmc.2021.116156","volume":"39","author":"A Bertokova","year":"2021","unstructured":"Bertokova A, Bertok T, Jane E, Hires M, \u010eubjakov\u00e1 P, Novotn\u00e1 O, et al. Detection of N,N-diacetyllactosamine (LacdiNAc) containing free prostate-specific antigen for early stage prostate cancer diagnostics and for identification of castration-resistant prostate cancer patients. Bioorg Med Chem. 2021;39:116156. https:\/\/doi.org\/10.1016\/j.bmc.2021.116156.","journal-title":"Bioorg Med Chem"},{"key":"9617_CR140","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1002\/pros.21375","volume":"71","author":"SA Williams","year":"2011","unstructured":"Williams SA, Jelinek CA, Litvinov I, Cotter RJ, Isaacs JT, Denmeade SR. Enzymatically active prostate-specific antigen promotes growth of human prostate cancers. Prostate. 2011;71:1595\u2013607. https:\/\/doi.org\/10.1002\/pros.21375.","journal-title":"Prostate"},{"key":"9617_CR141","doi-asserted-by":"publisher","first-page":"82","DOI":"10.5152\/tud.2014.94547","volume":"40","author":"SN Ayy\u0131ld\u0131z","year":"2019","unstructured":"Ayy\u0131ld\u0131z SN, PSA. PSA derivatives, proPSA and prostate health index in the diagnosis of prostate cancer. Urol Res Pract. 2019;40:82\u20138. https:\/\/doi.org\/10.5152\/tud.2014.94547.","journal-title":"Urol Res Pract"},{"key":"9617_CR142","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1515\/cclm-2022-0354","volume":"60","author":"L Agnello","year":"2022","unstructured":"Agnello L, Vidali M, Giglio RV, Gambino CM, Ciaccio AM, Lo Sasso B, et al. Prostate health index (PHI) as a reliable biomarker for prostate cancer: a systematic review and meta-analysis. Clin Chem Lab Med (CCLM). 2022;60:1261\u201377. https:\/\/doi.org\/10.1515\/cclm-2022-0354.","journal-title":"Clin Chem Lab Med (CCLM)"},{"key":"9617_CR143","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.canep.2017.12.002","volume":"52","author":"J Leal","year":"2018","unstructured":"Leal J, Welton NJ, Martin RM, Donovan J, Hamdy F, Neal D, et al. Estimating the sensitivity of a prostate cancer screening programme for different PSA cut-off levels: A UK case study. Cancer Epidemiol. 2018;52:99\u2013105. https:\/\/doi.org\/10.1016\/j.canep.2017.12.002.","journal-title":"Cancer Epidemiol"},{"key":"9617_CR144","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1002\/pros.70014","volume":"85","author":"H Koistinen","year":"2025","unstructured":"Koistinen H, Merivirta R, Lehto T, Lempi\u00e4inen A, Erickson A, Stenman U, et al. Altered Glycosylation of PSA in Prostate Cancer Tissue. Prostate. 2025;85:1290\u20138. https:\/\/doi.org\/10.1002\/pros.70014.","journal-title":"Prostate"},{"key":"9617_CR145","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41391-024-00920-1","volume":"28","author":"U Stopka-Farooqui","year":"2025","unstructured":"Stopka-Farooqui U, Stavrinides V, Simpson BS, Qureshi H, Carmona Echevierra LM, Pye H, et al. Combining tissue biomarkers with mpMRI to diagnose clinically significant prostate cancer. Analysis of 21 biomarkers in the PICTURE study. Prostate Cancer Prostatic Dis. 2025;28:457\u201368. https:\/\/doi.org\/10.1038\/s41391-024-00920-1.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"9617_CR146","doi-asserted-by":"publisher","first-page":"e1357","DOI":"10.1002\/cnr2.1357","volume":"4","author":"VG Wagaskar","year":"2021","unstructured":"Wagaskar VG, Sobotka S, Ratnani P, Young J, Lantz A, Parekh S, et al. A 4K score\/MRI-based nomogram for predicting prostate cancer, clinically significant prostate cancer, and unfavorable prostate cancer. Cancer Rep (Hoboken). 2021;4:e1357. https:\/\/doi.org\/10.1002\/cnr2.1357.","journal-title":"Cancer Rep (Hoboken)"},{"key":"9617_CR147","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.euo.2019.08.015","volume":"3","author":"UG Falagario","year":"2020","unstructured":"Falagario UG, Martini A, Wajswol E, Treacy P-J, Ratnani P, Jambor I, et al. Avoiding Unnecessary Magnetic Resonance Imaging (MRI) and Biopsies: Negative and Positive Predictive Value of MRI According to Prostate-specific Antigen Density, 4Kscore and Risk Calculators. Eur Urol Oncol. 2020;3:700\u20134. https:\/\/doi.org\/10.1016\/j.euo.2019.08.015.","journal-title":"Eur Urol Oncol"},{"key":"9617_CR148","doi-asserted-by":"publisher","first-page":"101161","DOI":"10.1016\/j.eclinm.2021.101161","volume":"43","author":"Z Yang","year":"2022","unstructured":"Yang Z, Bai H, Hu L, Kong D, Li G, Zhao C, et al. Improving the diagnosis of prostate cancer by telomerase-positive circulating tumor cells: A prospective pilot study. EClinicalMedicine. 2022;43:101161. https:\/\/doi.org\/10.1016\/j.eclinm.2021.101161.","journal-title":"EClinicalMedicine"},{"key":"9617_CR149","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/CCO.0000000000000439","volume":"30","author":"K Bouchelouche","year":"2018","unstructured":"Bouchelouche K, Choyke PL. Advances in prostate-specific membrane antigen PET of prostate cancer. Curr Opin Oncol. 2018;30:189\u201396. https:\/\/doi.org\/10.1097\/CCO.0000000000000439.","journal-title":"Curr Opin Oncol"},{"key":"9617_CR150","doi-asserted-by":"publisher","unstructured":"Agbetuyi-Tayo P, Gbadebo M, Rotimi OA, Rotimi SO. Advancements in Biomarkers of Prostate Cancer: A Review. Technol Cancer Res Treat. 2024;23. https:\/\/doi.org\/10.1177\/15330338241290029.","DOI":"10.1177\/15330338241290029"},{"key":"9617_CR151","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s11934-023-01149-6","volume":"24","author":"TN Chu","year":"2023","unstructured":"Chu TN, Wong EY, Ma R, Yang CH, Dalieh IS, Hung AJ. Exploring the Use of Artificial Intelligence in the Management of Prostate Cancer. Curr Urol Rep. 2023;24:231\u201340. https:\/\/doi.org\/10.1007\/s11934-023-01149-6.","journal-title":"Curr Urol Rep"},{"key":"9617_CR152","doi-asserted-by":"publisher","unstructured":"Bhattacharya I, Khandwala YS, Vesal S, Shao W, Yang Q, Soerensen SJC, et al. A review of artificial intelligence in prostate cancer detection on imaging. Ther Adv Urol. 2022;14. https:\/\/doi.org\/10.1177\/17562872221128791.","DOI":"10.1177\/17562872221128791"},{"key":"9617_CR153","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.96226","author":"MR Hasan","year":"2025","unstructured":"Hasan MR, Ibraheem N, Rahman ME, Tamanna R. Artificial Intelligence Across the Prostate Cancer Pathway: Screening, Imaging, Pathology, and Biomarkers. Cureus. 2025. https:\/\/doi.org\/10.7759\/cureus.96226.","journal-title":"Cureus"},{"key":"9617_CR154","doi-asserted-by":"publisher","unstructured":"Al Barajraji M, Coscarella M, Svistakov I, Fl\u00f4res Soares da Silva H, D\u00e9niz PM, Marugan MJ et al. Beyond PSA: The Future of Prostate Cancer Diagnosis Using Artificial Intelligence, Novel Biomarkers, and Advanced Imagery. 2025;15:1508. https:\/\/doi.org\/10.3390\/life15101508","DOI":"10.3390\/life15101508"},{"key":"9617_CR155","doi-asserted-by":"publisher","unstructured":"Rajih E, Bakhsh A, Borhan WM, Alqahtani SAM. Utilization of artificial intelligence in prostate cancer detection: a comprehensive review of innovations in screening and diagnosis. Front Immunol. 2025;16. https:\/\/doi.org\/10.3389\/fimmu.2025.1670671.","DOI":"10.3389\/fimmu.2025.1670671"},{"key":"9617_CR156","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.ajur.2024.12.001","volume":"12","author":"Y Arita","year":"2025","unstructured":"Arita Y, Roest C, Kwee TC, Paudyal R, Lema-Dopico A, Fransen S, et al. Advancements in artificial intelligence for prostate cancer: Optimizing diagnosis, treatment, and prognostic assessment. Asian J Urol. 2025;12:434\u201344. https:\/\/doi.org\/10.1016\/j.ajur.2024.12.001.","journal-title":"Asian J Urol"},{"key":"9617_CR157","doi-asserted-by":"publisher","unstructured":"Haider M, Leow JJ, Nordstr\u00f6m T, Mortezavi A, Albers P, Heer R, et al. Emerging tools for the early detection of prostate cancer. BJUI Compass. 2025;6. https:\/\/doi.org\/10.1002\/bco2.70081.","DOI":"10.1002\/bco2.70081"},{"key":"9617_CR158","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s40164-023-00444-9","volume":"12","author":"GL Varaprasad","year":"2023","unstructured":"Varaprasad GL, Gupta VK, Prasad K, Kim E, Tej MB, Mohanty P, et al. Recent advances and future perspectives in the therapeutics of prostate cancer. Exp Hematol Oncol. 2023;12:80. https:\/\/doi.org\/10.1186\/s40164-023-00444-9.","journal-title":"Exp Hematol Oncol"},{"key":"9617_CR159","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s13402-016-0268-6","volume":"39","author":"S Saini","year":"2016","unstructured":"Saini S. PSA and beyond: alternative prostate cancer biomarkers. Cell Oncol. 2016;39:97\u2013106. https:\/\/doi.org\/10.1007\/s13402-016-0268-6.","journal-title":"Cell Oncol"},{"key":"9617_CR160","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.tibtech.2004.06.005","volume":"22","author":"SE Ilyin","year":"2004","unstructured":"Ilyin SE, Belkowski SM, Plata-Salam\u00e1n CR. Biomarker discovery and validation: technologies and integrative approaches. Trends Biotechnol. 2004;22:411\u20136. https:\/\/doi.org\/10.1016\/j.tibtech.2004.06.005.","journal-title":"Trends Biotechnol"},{"key":"9617_CR161","doi-asserted-by":"publisher","unstructured":"Melichar B, Plebani M. Laboratory medicine: an essential partner in the care of cancer patients. Clin Chem Lab Med. 2011;49. https:\/\/doi.org\/10.1515\/CCLM.2011.244.","DOI":"10.1515\/CCLM.2011.244"},{"key":"9617_CR162","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1097\/00005392-199501000-00037","volume":"153","author":"E Rogers","year":"1995","unstructured":"Rogers E, Ohori M, Kassabian VS, Wheeler TM, Scardino PT. Salvage Radical Prostatectomy: Outcome Measured by Serum Prostate Specific Antigen Levels. J Urol. 1995;153:104\u201310. https:\/\/doi.org\/10.1097\/00005392-199501000-00037.","journal-title":"J Urol"},{"key":"9617_CR163","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1001\/jama.2017.7248","volume":"317","author":"MS Litwin","year":"2017","unstructured":"Litwin MS, Tan H-J. The Diagnosis and Treatment of Prostate Cancer. JAMA. 2017;317:2532. https:\/\/doi.org\/10.1001\/jama.2017.7248.","journal-title":"JAMA"},{"key":"9617_CR164","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1515\/cclm-2013-0156","volume":"51","author":"B Melichar","year":"2013","unstructured":"Melichar B, PSA. PCA3 and the phi losophy of prostate cancer management. Clin Chem Lab Med (CCLM). 2013;51:707\u201312. https:\/\/doi.org\/10.1515\/cclm-2013-0156.","journal-title":"Clin Chem Lab Med (CCLM)"},{"key":"9617_CR165","doi-asserted-by":"publisher","unstructured":"Rice A, Stoyanova M. T. Biomarkers for Diagnosis and Prognosis of Prostate Cancer. Prostatectomy. IntechOpen; 2019. https:\/\/doi.org\/10.5772\/intechopen.79726","DOI":"10.5772\/intechopen.79726"},{"key":"9617_CR166","doi-asserted-by":"publisher","unstructured":"Tikkinen KAO, Dahm P, Lytvyn L, Heen AF, Vernooij RWM, Siemieniuk RAC, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline. BMJ. 2018;k3581. https:\/\/doi.org\/10.1136\/bmj.k3581.","DOI":"10.1136\/bmj.k3581"},{"key":"9617_CR167","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1001\/jama.1997.03540420041027","volume":"277","author":"AW Partin","year":"1997","unstructured":"Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA. 1997;277:1445\u201351.","journal-title":"JAMA"},{"key":"9617_CR168","doi-asserted-by":"publisher","first-page":"20802","DOI":"10.18632\/oncotarget.14903","volume":"8","author":"FM Chinea","year":"2017","unstructured":"Chinea FM, Lyapichev K, Epstein JI, Kwon D, Taylor Smith P, Pollack A, et al. Understanding PSA and its derivatives in prediction of tumor volume: addressing health disparities in prostate cancer risk stratification. Oncotarget. 2017;8:20802\u201312. https:\/\/doi.org\/10.18632\/oncotarget.14903.","journal-title":"Oncotarget"},{"key":"9617_CR169","doi-asserted-by":"publisher","unstructured":"Butler W, Huang J. Glycosylation Changes in Prostate Cancer Progression. Front Oncol. 2021;11. https:\/\/doi.org\/10.3389\/fonc.2021.809170.","DOI":"10.3389\/fonc.2021.809170"},{"key":"9617_CR170","first-page":"14","volume":"11","author":"CJ Paller","year":"2013","unstructured":"Paller CJ, Antonarakis ES. Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions. Clin Adv Hematol Oncol. 2013;11:14\u201323.","journal-title":"Clin Adv Hematol Oncol"},{"key":"9617_CR171","doi-asserted-by":"publisher","unstructured":"Spratt DE, McHugh DJ, Morris MJ, Morgans AK. Management of Biochemically Recurrent Prostate Cancer: Ensuring the Right Treatment of the Right Patient at the Right Time. Am Soc Clin Oncol Educational Book. 2018;355\u201362. https:\/\/doi.org\/10.1200\/EDBK_200319.","DOI":"10.1200\/EDBK_200319"},{"key":"9617_CR172","doi-asserted-by":"publisher","first-page":"dju010","DOI":"10.1093\/jnci\/dju010","volume":"106","author":"TJ Wilt","year":"2014","unstructured":"Wilt TJ, Scardino PT, Carlsson SV, Basch E. Prostate-Specific Antigen Screening in Prostate Cancer: Perspectives on the Evidence. JNCI J Natl Cancer Inst. 2014;106:dju010\u2013010. https:\/\/doi.org\/10.1093\/jnci\/dju010.","journal-title":"JNCI J Natl Cancer Inst"},{"key":"9617_CR173","doi-asserted-by":"publisher","unstructured":"Guo Y, Jia W, Yang J, Zhan X. Cancer glycomics offers potential biomarkers and therapeutic targets in the framework of 3P medicine. Front Endocrinol (Lausanne). 2022;13. https:\/\/doi.org\/10.3389\/fendo.2022.970489.","DOI":"10.3389\/fendo.2022.970489"},{"key":"9617_CR174","doi-asserted-by":"publisher","first-page":"100565","DOI":"10.1016\/j.mcpro.2023.100565","volume":"22","author":"Y van der Burgt","year":"2023","unstructured":"van der Burgt Y, Wuhrer M. The Role of Clinical Glyco(proteo)mics in Precision Medicine. Mol Cell Proteom. 2023;22:100565. https:\/\/doi.org\/10.1016\/j.mcpro.2023.100565.","journal-title":"Mol Cell Proteom"},{"key":"9617_CR175","doi-asserted-by":"publisher","first-page":"455e1","DOI":"10.1016\/j.urolonc.2023.08.011","volume":"41","author":"CM de la Calle","year":"2023","unstructured":"de la Calle CM, Jing Y, Mamawala MM, Landis P, Macura KJ, Trock BJ, et al. Baseline prostate health index risk category and risk category changes during active surveillance predict grade reclassification. Urologic Oncology: Seminars Original Investigations. 2023;41:455e1. https:\/\/doi.org\/10.1016\/j.urolonc.2023.08.011.","journal-title":"Urologic Oncology: Seminars Original Investigations"},{"key":"9617_CR176","doi-asserted-by":"publisher","first-page":"762","DOI":"10.3390\/biology13100762","volume":"13","author":"S Hachem","year":"2024","unstructured":"Hachem S, Yehya A, El Masri J, Mavingire N, Johnson JR, Dwead AM, et al. Contemporary Update on Clinical and Experimental Prostate Cancer Biomarkers: A Multi-Omics-Focused Approach to Detection and Risk Stratification. Biology (Basel). 2024;13:762. https:\/\/doi.org\/10.3390\/biology13100762.","journal-title":"Biology (Basel)"},{"key":"9617_CR177","doi-asserted-by":"publisher","first-page":"436","DOI":"10.4111\/kju.2014.55.7.436","volume":"55","author":"A Abrate","year":"2014","unstructured":"Abrate A, Lughezzani G, Gadda GM, Lista G, Kinzikeeva E, Fossati N, et al. Clinical Use of [-2]proPSA (p2PSA) and Its Derivatives (%p2PSA and Prostate Health Index) for the Detection of Prostate Cancer: A Review of the Literature. Korean J Urol. 2014;55:436. https:\/\/doi.org\/10.4111\/kju.2014.55.7.436.","journal-title":"Korean J Urol"},{"key":"9617_CR178","doi-asserted-by":"publisher","first-page":"e0300430","DOI":"10.1371\/journal.pone.0300430","volume":"19","author":"A Pinkeova","year":"2024","unstructured":"Pinkeova A, Tomikova A, Bertokova A, Fabinyova E, Bartova R, Jane E, et al. Glycoprofiling of proteins as prostate cancer biomarkers: A multinational population study. PLoS ONE. 2024;19:e0300430. https:\/\/doi.org\/10.1371\/journal.pone.0300430.","journal-title":"PLoS ONE"},{"key":"9617_CR179","doi-asserted-by":"publisher","first-page":"236","DOI":"10.21037\/tau.2018.02.08","volume":"7","author":"AS Glass","year":"2018","unstructured":"Glass AS, Dall\u2019Era MA. Indications for and transitioning to secondary treatment while on active surveillance for prostate cancer. Transl Androl Urol. 2018;7:236\u201342. https:\/\/doi.org\/10.21037\/tau.2018.02.08.","journal-title":"Transl Androl Urol"},{"key":"9617_CR180","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1200\/JCO.2006.08.9607","volume":"25","author":"AJ Stephenson","year":"2007","unstructured":"Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, et al. Predicting the Outcome of Salvage Radiation Therapy for Recurrent Prostate Cancer After Radical Prostatectomy. J Clin Oncol. 2007;25:2035\u201341. https:\/\/doi.org\/10.1200\/JCO.2006.08.9607.","journal-title":"J Clin Oncol"},{"key":"9617_CR181","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/j.1464-410X.2007.07283.x","volume":"101","author":"SF Shariat","year":"2008","unstructured":"Shariat SF, Karam JA, Margulis V, Karakiewicz PI. New blood-based biomarkers for the diagnosis, staging and prognosis of prostate cancer. BJU Int. 2008;101:675\u201383. https:\/\/doi.org\/10.1111\/j.1464-410X.2007.07283.x.","journal-title":"BJU Int"},{"key":"9617_CR182","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/CU9.0000000000000145","volume":"16","author":"A Tidd-Johnson","year":"2022","unstructured":"Tidd-Johnson A, Sebastian SA, Co EL, Afaq M, Kochhar H, Sheikh M, et al. Prostate cancer screening: Continued controversies and novel biomarker advancements. Curr Urol. 2022;16:197\u2013206. https:\/\/doi.org\/10.1097\/CU9.0000000000000145.","journal-title":"Curr Urol"},{"key":"9617_CR183","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1515\/cclm-2019-0693","volume":"58","author":"MJ Duffy","year":"2020","unstructured":"Duffy MJ. Biomarkers for prostate cancer: prostate-specific antigen and beyond. Clin Chem Lab Med (CCLM). 2020;58:326\u201339. https:\/\/doi.org\/10.1515\/cclm-2019-0693.","journal-title":"Clin Chem Lab Med (CCLM)"},{"key":"9617_CR184","doi-asserted-by":"publisher","first-page":"98","DOI":"10.21037\/tau.2017.12.28","volume":"7","author":"F-JH Drost","year":"2018","unstructured":"Drost F-JH, Rannikko A, Valdagni R, Pickles T, Kakehi Y, Remmers S, et al. Can active surveillance really reduce the harms of overdiagnosing prostate cancer? A reflection of real life clinical practice in the PRIAS study. Transl Androl Urol. 2018;7:98\u2013105. https:\/\/doi.org\/10.21037\/tau.2017.12.28.","journal-title":"Transl Androl Urol"},{"key":"9617_CR185","doi-asserted-by":"publisher","first-page":"5386","DOI":"10.3390\/ijms26115386","volume":"26","author":"S Vakili","year":"2025","unstructured":"Vakili S, Beheshti I, Barzegar Behrooz A, \u0141os MJ, Vitorino R, Ghavami S. Transforming Prostate Cancer Care: Innovations in Diagnosis, Treatment, and Future Directions. Int J Mol Sci. 2025;26:5386. https:\/\/doi.org\/10.3390\/ijms26115386.","journal-title":"Int J Mol Sci"},{"key":"9617_CR186","doi-asserted-by":"publisher","first-page":"150","DOI":"10.7150\/jca.1.150","volume":"1","author":"CO Madu","year":"2010","unstructured":"Madu CO, Lu Y. Novel diagnostic biomarkers for prostate cancer. J Cancer. 2010;1:150\u201377. https:\/\/doi.org\/10.7150\/jca.1.150.","journal-title":"J Cancer"}],"container-title":["Clinical Proteomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12014-026-09617-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12014-026-09617-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12014-026-09617-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:03:33Z","timestamp":1790687013000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12014-026-09617-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,28]]},"references-count":186,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["9617"],"URL":"https:\/\/doi.org\/10.1186\/s12014-026-09617-0","relation":{"references":[{"id-type":"doi","id":"10.2147\/RRU.S331506","asserted-by":"subject"}]},"ISSN":["1542-6416","1559-0275"],"issn-type":[{"value":"1542-6416","type":"print"},{"value":"1559-0275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,28]]},"assertion":[{"value":"2 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"46"}}